Mount Lucas Management LP Makes New Investment in Cencora, Inc. $COR

Mount Lucas Management LP purchased a new stake in shares of Cencora, Inc. (NYSE:COR) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 6,569 shares of the company’s stock, valued at approximately $1,970,000. Cencora makes up approximately 0.8% of Mount Lucas Management LP’s portfolio, making the stock its 24th largest position.

Several other hedge funds and other institutional investors have also modified their holdings of COR. Atlantic Edge Private Wealth Management LLC grew its stake in Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares in the last quarter. Obermeyer Wealth Partners lifted its holdings in shares of Cencora by 1.3% during the 1st quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company’s stock valued at $758,000 after buying an additional 36 shares during the last quarter. Grove Bank & Trust grew its stake in shares of Cencora by 4.3% in the 2nd quarter. Grove Bank & Trust now owns 879 shares of the company’s stock valued at $264,000 after buying an additional 36 shares in the last quarter. U.S. Capital Wealth Advisors LLC increased its holdings in Cencora by 0.4% in the second quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock worth $2,563,000 after buying an additional 38 shares during the last quarter. Finally, Monument Capital Management increased its holdings in Cencora by 2.4% in the second quarter. Monument Capital Management now owns 1,637 shares of the company’s stock worth $491,000 after buying an additional 38 shares during the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on COR. Evercore ISI set a $400.00 target price on shares of Cencora and gave the company an “outperform” rating in a research note on Thursday, November 6th. UBS Group increased their target price on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. TD Cowen boosted their price target on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Weiss Ratings reissued a “buy (b-)” rating on shares of Cencora in a report on Thursday, October 30th. Finally, Wall Street Zen raised Cencora from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $371.09.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the transaction, the chief executive officer owned 37,940 shares in the company, valued at $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 41,544 shares of company stock valued at $12,230,941 over the last quarter. Corporate insiders own 10.80% of the company’s stock.

Cencora Price Performance

Shares of NYSE:COR opened at $361.97 on Monday. Cencora, Inc. has a twelve month low of $223.92 and a twelve month high of $369.00. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The company has a market cap of $70.18 billion, a price-to-earnings ratio of 37.24, a PEG ratio of 1.56 and a beta of 0.63. The business has a 50 day moving average price of $321.35 and a 200 day moving average price of $302.23.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. During the same quarter last year, the company posted $3.34 earnings per share. Cencora’s quarterly revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be paid a dividend of $0.60 per share. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, November 14th. Cencora’s dividend payout ratio is currently 30.19%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.